The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.
Abstract
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2. During 4-h oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min) plus exendin(9-39)NH2 (0–20 min: 1,000 pmol/kg/min; 20–240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively. Glucose excursions were significantly higher during A than during B, C, and D, while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide/glucose ratio) was reduced by 37 ± 16% (A), 30 ± 17% (B), and 8.6 ± 16% (C) compared with D (mean ± SD). A and C resulted in higher glucagon levels and faster gastric emptying. In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucose-dependent insulinotropic polypeptide is the primary incretin hormone responsible for mealstimulated insulin secretion in healthy individuals.7”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [7]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578 · cited 2×
“5A and Table 2]), may contribute to explain the lack of effect of exendin(9-39)NH2 on typical GLP-1 effects such as food intake and insulin secretion as previously described (31,43,48).”
BackgroundNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 9×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 8×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialSelf-citationVagal, Cholinergic Regulation of Pancreatic Polypeptide Secretion
Schwartz, T. W., Holst, J. J., Fahrenkrug, J., Jensen, S. L., Nielsen, O. V., Rehfeld, J. F., de Muckadell, O. B. S., & Stadil, F. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108992 · Cited by 386
Self-citationGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 8×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323
Jørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, D., Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, S., & Holst, J. J. (2013) · Diabetes · doi:10.2337/db13-0022 · Cited by 288
Self-citationDirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Jacobsen, S. H., Clausen, T. R., Worm, D., Hartmann, B., Rehfeld, J. F., Damgaard, M., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.15 · Cited by 276
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 232
Self-citationImpaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188
Self-citationSvane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 5×
“In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2.”
BackgroundMethodInfluentialSelf-citationISEC: a program to calculate insulin secretion
Hovorka, R., Soons, P. A., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 177
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Jorsal, T., Rhee, N. A., Pedersen, J., Wahlgren, C. D., Mortensen, B., Jepsen, S. L., Jelsing, J., Dalbøge, L. S., Vilmann, P., Hassan, H., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4450-9 · Cited by 172
Self-citationGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · cited 1×
“Appetite GLP-1 reduces energy intake via peripheral and central neuronal pathways (41), and in obese individuals, exendin (9-39)NH2 has been shown to increase food intake (42).”
BackgroundSelf-citationEdholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Self-citationHansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P. N., & Holst, J. J. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.6.e1010 · Cited by 147
Self-citationShah, M., Law, J. H., Micheletto, F., Sathananthan, M., Man, C. D., Cobelli, C., Rizza, R. A., Camilleri, M., Zinsmeister, A. R., & Vella, A. V. (2013) · Diabetes · doi:10.2337/db13-0954 · Cited by 143
Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans
Nissen, A. A., Christensen, M., Knop, F. K., Vilsbøll, T., Holst, J. J., & Hartmann, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2547 · Cited by 137
Self-citationAsmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132 · cited 5×
“In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2.”
BackgroundMethodInfluentialSelf-citationD’Alessio, D. A., Vogel, R., Prigeon, R. L., Laschansky, E. C., Koerker, D. J., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 119
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
Gasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 103
Self-citationHansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13384 · Cited by 97
Self-citationOn the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K. J., Astrup, A. V., Flint, A., Bülow, J., & Holst, J. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 91
Self-citationGLP‐1 regulates gastroduodenal motility involving cholinergic pathways
Schirra, J. R. J., Nicolaus, M., Woerle, H. J., Struckmeier, C. A., Katschinski, M., & Göke, B. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01246.x · Cited by 86
Gabe, M., Sparre-Ulrich, A. H., Pedersen, M. F., Gasbjerg, L., Inoue, A., Bräuner-Osborne, H., Hartmann, B., & Rosenkilde, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 84
Self-citationValidation of methods for measurement of insulin secretion in humans in vivo.
Kjems, L., Christiansen, E., Vølund, A., Bergman, R. N., & Madsbad, S. (2000) · Diabetes · doi:10.2337/diabetes.49.4.580 · Cited by 83
Sparre‐Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 83
Self-citationEffects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery
Svane, M. S., Bojsen-Møller, K. N., Nielsen, S. T., Jørgensen, N. B., Dirksen, C., Bendtsen, F., Kristiansen, V. B., Hartmann, B., Holst, J. J., & Madsbad, S. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2015 · Cited by 74
Self-citationWoerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 69
Effect of Glucagon-like Peptide-1 Receptor Antagonism on Appetite and Food Intake in Healthy Men
Steinert, R. E., Schirra, J., Meyer-Gerspach, A. C., Kienle, P., Fischer, H., Schulte, F., Goeke, B., & Beglinger, C. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.083246 · Cited by 52
Nauck, M. A., Kind, J., Köthe, L., Holst, J. J., Deacon, C. F., Broschag, M., He, Y. L., Kjems, L., & Foley, J. E. (2016) · Diabetes · doi:10.2337/db16-0107 · Cited by 52
Self-citationEffects of meal and incretins in the regulation of splanchnic blood flow
Koffert, J., Honka, H., Teuho, J., Kauhanen, S. P., Hurme, S. A. M., Parkkola, R. K., Oikonen, V., Mari, A., Lindqvist, A., Wierup, N., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0015 · Cited by 48
Yabe, D., Seino, Y., & Seino, Y. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12718 · Cited by 23
Research works printed but not linked: 2
- Pacini, 2005, The insulinogenic index is a valid marker of beta cell function in different metabolic categories, Diabetes, 54, A370
- Bergmann, 2017, The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects, Diabetologia, 60, S5
Cited by
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Metadata
- Authors
- Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2019-01-09
- Volume
- 68
- Issue
- 5
- Pages
- 906-917
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2909748938
- Semantic Scholar
- 8d259751958bd756f4a81231f9791af24dbcf3b4
- Cited by
- 193
- References
- 52
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 34 · 2023: 21 · 2022: 25 · 2021: 26 · 2020: 18 · 2019: 24
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, postprandial glucose regulation, GIP receptor antagonist, exendin-9-39, insulin secretion, glucagon, gastric emptying, oral glucose tolerance test, healthy men
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Glucose Tolerance Test, Humans, Infusions, Intravenous, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Postprandial Period, Glucagon-Like Peptide 1, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.